Answered 2/4/2015 by Samuel Grossman, BS Pharm, Pharm.D, CDE
The Food and Drug Administration approved Glyxambi, which is a combination of empagliflozin andl inagliptin tablets for adults with type 2 diabetes. This medication is a new combination of 2 medications that are already on the market. One medication is empagliflozin, which is a Sodium Glucose Transporter inhibitor type 2; and the other medication in the combination product is linagliptin, a DPP-4 inhibitor. Glyxambi has the benefit of improving compliance with medication therapy and allows the patient to take 1 tablet instead of 2.